Press "Enter" to skip to content

Understanding the biosimilars opportunity for Indian pharma

Several drugs classified as biologics are expected to go off patent during this period thereby making way for their biosimilar counterparts. Indian pharma companies active in this field are expected to be among the biggest beneficiaries of this opportunity.

Original source:

Also Read:   USFDA makes 'certain' observations for Torrent Pharma's Indrad plant